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Purpose/Objective: To compare dose sparing to stomach, duodenum 
and small bowel using radiobiological endpoints for 3D and intensity-
modulated arctherapy (IMAT) plans for locally advanced pancreatic 
cancer (LAPC). 
Materials and Methods: For 11 patients treated with chemo-
radiotherapy, the original 3D conformal treatment plan (50.4 Gy / 28 
fr to the tumour and elective nodes, PTV5040, then 9 Gy / 5 fr to the 
primary tumour, PTV5940) was compared retrospectively to an IMAT 
plan with a simultaneous integrated boost(59.4 Gy (PTV5940) and 52 
Gy (PTV5040) in 33 fractions). In both techniques, target coverage 
(D99% >95% prescribed dose) and dose constraints to critical organs 
(cord Dmax< 40 Gy, liver D50% <20 Gy and kidneys, R kidney D50%< 20 Gy, 
L kidney D30% < 20 Gy) were strictly respected. Plans were compared 
using the PTV conformity index CI95% and dose metrics of gastro-
intestinal (GI) organs (stomach: V50 and Dmax to 2cc, combined stomach 
and duodenum (StoDuo): V50 and small bowel: V45). NTCP modelling of 
stomach, duodenum and small bowel was used to rank plans by 
estimating GI toxicity, using the full range of NTCP parameter values 
for these organs found in the literature. 
Results: Improved dose sparing of critical organs for all 11 patients 
was observed with the IMAT technique, due to higher dose 
conformation of the target volume: IMAT mean PTV5940 CI95%= 1.08 ± 
0.03 vs 3D mean PTV5940 CI95% = 1.83 ± 0.25, p<0.001. In particular, 
dose constraints for L kidney were met for 11/11 patients for IMAT 
and only 6/11 for 3D. A reduction in acute toxicity of small bowel may 
be possible using IMAT due to the reduction of the V45 volume (IMAT 
mean 285.1 ±124.1 cm3 vs 3D mean 348.8±147.3 cm3, p<0.001). A 
similar reduction in high dose was seen for StoDuo when using IMAT: 
StoDuo V50 (IMAT mean 26.4±5.8 cm3 vs 3D mean 33.7±8.1 cm3 
p<0.0001). For stomach, although there was no significant difference 
in the two techniques for the Stomach Dmax (3D mean = 59.7±2.6 Gy 
and IMAT mean= 58.3±3.6 Gy), a reduction in the Stomach V50 volume 
was observed with IMAT (IMAT mean 18.7±12.3 cm3 vs 3D mean 
28.1±20.4 cm3, p=0.009). Using NTCP estimates of GI toxicity to rank 
plans showed that the IMAT technique was always preferable to 3D 
conformal therapy, independent of the values used in the 
radiobiological modelling.  
Conclusions: The predicted dose sparing obtained with the IMAT 
technique is particularly important in the context of concurrent 
chemo-radiotherapy for pancreatic cancer where GI toxicity is often a 
limiting factor. For stomach, duodenum and small bowel, NTCP 
analysis predicts a significant advantage in using IMAT. Using 
radiobiological endpoints presents a simple method for obtaining 
relative plan ranking, which is robust to the choice of values used in 
the NTCP modelling.  
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Purpose/Objective: Higher tumour stage is an independent predictor 
of local failure. We present a retrospective planning study to 
determine the feasibility of dose escalation in very advanced anal 
cancers using a simultaneous integrated boost (SIB) with a small bowel 
dose constraint of V30Gy≤300cc (Devisetty et al 2009).  
Materials and Methods: Five consecutive CT datasets of patients with 
stage T3N2-T4N3 anal canal were identified. Planning target volume 1 
(PTV1) included tumour and pelvic elective nodal areas; PTV2 
included primary tumour and involved nodes. Three types of IMRT 
plans were generated. The CLINICAL plan utilised a sequential phase1 
inverse-planned 7-field IMRT followed by either a conformal or 
inverse-planned phase 2. The SIB plans were prescribed 42Gy in 
1.5Gy/fraction to PTV 1 and 50.4Gy (SIB1.8) and 56Gy (SIB2.0) to PTV2 
respectively. Prescription dose to the CLINICAL plan was 30.6Gy and 
19.8Gy in 1.8Gy/fractions to PTV1 and PTV2 respectively. The plans 
were optimised to meet small bowel, genitalia, bladder and femoral 
head constraints. Patients were previously treated with the CLINICAL 
plan and did not experience high grade acute bowel toxicity. 
Maintaining the same risk of gastro-intestinal toxicity as achieved in 
the CLINICAL plan was a priority. The CLINICAL plan was used as the 
reference and the small bowel dose constraint V30Gy≤300cc was aimed 
for in the SIB plans. Small bowel V30Gy and coverage of PTV2 by 95% 
prescription isodose and conformity index (CI) were compared.  
Results: All plans achieved the minimum dose coverage of 95% 
prescription dose. No plan exceeded a maximum dose of 105% to 2% of 
the PTV volume. The SIB test arms had better conformity index (CI) 
than the clinical plan. 4/5 patients met the bowel dose constraint of 
V30Gy≤300cc. One case failed to achieve small bowel constraint as 
223cc bowel overlapped PTV. 
 









PTV D98% (Gy) 49.0 (48-49.4) 48.3 (47.9-48.5) 53.5 (53.5-53.9) 
PTV D2% (Gy) 51.9 (51.7-52.3) 52.3 (52.2-52.4) 58 (57.8-58.4) 
PTV D50% (Gy) 50.6 (50.4-50.7) 50.4 (50.4-50.5) 55.9 (55.9-56.1) 
PTV D95% (Gy) 49.3 (48.8-49.7) 48.7 (48.4-48.9) 54 (54-54.3) 
CI 1.40 1.15 1.15 
 
  
Conclusions: SIB IMRT is achievable whilst meeting the bowel 
constraint of V30Gy≤300cc providing that the physical volume of the 
bowel and PTV overlap is kept below 190cc. Acceptable small bowel 
dose increases are seen in the SIB plans compared to the clinical plan. 
Dose escalation is achievable for prescription doses of 50.4Gy and 
56Gy to the primary volume and plans for escalation to 64.4Gy are in 
progress. 
Reference 
Devisetty K, Mell LK, Salama JK et al. A multi-institutional acute 
gastrointestinal toxicity analysis of anal cancer patients treated with 
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Purpose/Objective: The accurate and fast dose calculation is an 
essential requirement of modern Radiotherapy (RT).The ability to 
predict dose with high accuracy is usually associated with the 
probabilistic Monte Carlo methods, but with long calculation times for 
use in daily clinical practice. The dose-calculation algorithms used in 
clinical practice, such as pencil-beam convolution and the 
convolution/superposition (method used in Anisotropic Analytical 
Algorithm - AAA) typically include models to significantly reduce the 
computation time (pre-calculated dose kernels in water with Monte 
Carlo), but with decreasing accuracy, especially in the presence of 
heterogeneities. The deterministic dose-calculation algorithm Acuros® 
XB for photons, which was recently implemented in the treatment 
planning system (TPS) Eclipse™ is able to fulfill these two 
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requirements. The aim of this study was to assess the dosimetric 
performance in clinical conditions of Acuros® XB in relation to AAA. 
Materials and Methods: The clinical dosimetric planning of 60 
patients who underwent treatment for RT, with Rapidarc™ technique 
and calculated with AAA where included in the study. The dosimetric 
plans werere calculated with the Acuros® XB, being compared and 
evaluated on dose-volume histograms (DVH) and radiobiological 
parameters. These 60 patients were divided into 3 groups of 20 
patients each (head and neck, thorax and pelvis). For both plans the 
relative dose values at 5 points of the cumulative DHV for PTV were 
collected: minimum dose (Dmin), near-minimum dose (D98%), medium 
dose (Dmed), near-maximal dose (D2%) and maximal dose (Dmax).  
Results: By comparing the data obtained in this study it was found 
that concerning the relative dose either in overall terms, or in terms 
of compartmental analysis of multiple groups of patients, the AAA 
overestimates the prediction of the dose for all evaluated DVH points 
except for Dmax. The comparison of the results of the averages 
calculated in the dosimetric plans for AAA and for the Acuros® XB 
suggest several scenarios: a reduction of the prescribed dose (Dmed) 
in 1.3%, a decrease also in the near-minimum dose (D98%), a decrease 
of 2.8% in Dmin and an increase in Dmax of 0.8%, which implies a 
decrease in the dose homogeneity inthe plan, and consequently the 
EUD is lower in all plans. 
Conclusions: With the growing interest in RT techniques of volumetric 
modulated arc therapy (VMAT) for various clinical applications, 
Acuros®XB can provide both accuracy and speed of calculation in 
treatment planning. 
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Purpose/Objective: To evaluate the dosimetric differences in term of 
target delineation, lung volume and dose delivered to the lungs 
between four respiratory movement management (RMM) techniques 
possibly used in lung tumours irradiation. 
Materials and Methods: Seven patients with one or more primary or 
secondary lung lesions less than 5 cm (11 tumours in total) had four 
CT: free-breathing CT (FB), two deep-inspiration breath-hold (DI-BH) 
CT using a spirometer, and a 4DCT based on the acquisition of ten 
respiratory phases. From these four acquisitions, five treatments plans 
were performed: FB (reference method), DI-BH, and three from the 
4DCT: two breathing synchronized treatments (inspiration (insp) and 
expiration (exp), both based on three phases) and one treatment 
taking into account all the tumours motions (based on ten phases, 
definition of the internal target volume (ITV)). Planning target volume 
(PTV) size and lungs size and dose delivered for the lungs were 
compared. 
Results: Mean PTV for the FB modality was 83 ± 28 cm3, which was 
significantly greater than any of the other techniques (p<0.0001) 
(figure (A)). Compared to the FB PTV, PTV defined with the ITV was 
reduced by one quarter (63 ± 31 cm3). PTV with the DI-BH, breathing 
synchronized inspiration and breathing synchronized expiration 
techniques were reduced by one third (50 to 54, ± 24 to 26 cm3). DI 
led to significantly increase the healthy lung volume compared to 
other methods (mean volume of 5500 ± 1500 cm3 versus 3540 to 3920 
cm3, respectively, p<0.0001) (figure (B)). The volume of healthy lungs 
receiving at least 5 and 20 Gy (V5 and V20) were significantly higher 
with the FB method than any of the other methods (p<0.0001) (figure 




Conclusions: First of all, the contouring strategy was different with 
the 4DCT and DI-BH techniques compared to the FB technique. In the 
two first cases, automatic margins were only used to create the PTV 
and only concerned the patient setup accuracy but not the tumour 
displacement, although with the FB technique non personalized and 
automatic margins were applied to create ITV and PTV. Secondly, DI-
BH technique provides the most significant dosimetric advantages: 
small PTV and large lung volume. However, patients must be able to 
hold 20 seconds of apnea, which moreover prevent to perfom CBCT 
images to setup the patient (duration about 45s). Respiratory gating 
(insp and exp) also reduces the PTV, but its application often requires 
the implantation of fiducial which limits its use and the treatment 
time is also important. Finally, an ITV technique allows for a 
personalized and reduced PTV compared to FB technique, and allows 
using CBCT to setup the patient without the implantation of fiducial. 
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Purpose/Objective: The 3D-CRT planning is usually done with trial 
method which is quite time consuming. In this work we tested the 
usage of dose gradient based algorithm for selection of beam weights 
in 3D-CRT plans. Our algorithm is easy to implement for three fields 
technique with wedges defined by planner.  
Materials and Methods: We assume that most homogenous dose 
distribution in target volume, for given set of beam angles and beam 
modifiers, is achieved when the dose gradient at ICRU Reference Point 
(chosen as isocenter point) is equal zero. Therefore calculation of 
beam weights is done in 2D by solving set of equations:  
∑ wi · Di (ICRU) = Dp (ICRU) ;  
∑ wi · grad Di (ICRU) = 0 
 (Di is dose from ith beam normalized to isocenter, Dp is prescribed 
dose, wi –weight of ith beam defined at the ICRU Reference Point). 
First equation guarantees that prescribed dose in isocenter should be 
equal Dp. Second equation sets dose gradient (here in 2D plane) to 
zero. Method was tested for 120 patients, treated in our clinic in 
2011-2012, with different cancer locations (prostate, lung, esophagus, 
rectum, gynecology, stomach). For each patient three fields 
conformal plan (6MV and 15 MV x-ray) with the same geometry as 
proposed by experienced planners were prepared. Beam weights were 
calculated with formulas given above. We compared dose distributions 
achieved with the proposed method and those prepared by 
experienced planners. All other modifications (wedges, MLC, jaws) 
were the same. Both plans were created with the Eclipse Treatment 
Planning System. The homogeneity of dose distributions of 
mathematically optimized and prepared by planners plans were 
compared. The homogeneity was expressed in terms of standard 
deviation and near minimum and maximum doses in the Planning 
Target Volume. All mathematical calculations were performed with 
the help of free Python language. 
Results: Mean difference of standard deviation obtained by the 
proposed algorithm and by planners (with trial-and-error forward 
planning process) was 0.1% (see histogram plot for details): 0.1% for 
prostate cancer, 0.3% for lung cancer, -0.1% for esophagus cancer, 
0.1% for rectum cancer, -0.1% for gynecology cancer, -0.1% for 
stomach cancer. Mean D98% difference was: -0.2% for prostate cancer, 
-0.4% for lung cancer, 0.2% for esophagus cancer, -0.1%for rectum 
cancer, 0.1% for gynecology cancer, 0.2% for stomach cancer. Mean 
D2% difference was: 0.3% for prostate cancer, 0.9% for lung cancer, -
0.1% for esophagus cancer, 0.3% for rectum cancer, 0.3% for 
gynecology cancer, 0.2% for stomach cancer. 
 
